Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback